Do Factor V Leiden and Prothrombin G20210A Mutations Predict Recurrent Venous Thromboembolism in Older Patients?

Méan, Marie; Limacher, Andreas; Stalder, Odile; Angelillo‐Scherrer, Anne; Alberio, Lorenzo; Fontana, Pierre

doi:10.1016/j.jvsv.2017.12.004

Cited by 5 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, in a study with of 354 consecutive patients aged ≥65 years with a first unprovoked VTE, 9.0% of patients had FVL and 3.7% had a F2 G20210A variant 66 . After adjustment for age, sex, and periods of anticoagulation as a time‐varying covariate, at 3‐year follow up neither the FVL (HR 0.98; 95% CI: 0.35–2.77) nor the F2 G20210A mutation (HR 1.15; 95% CI: 0.25–5.19) was associated with recurrent venous thromboembolism compared to controls 66 …”

Section: Thrombophilia Traits: Clinical Significance and Measurement ...mentioning

confidence: 97%

“…19) was associated with recurrent venous thromboembolism compared to controls. 66 Patients with natural anticoagulant deficiencies were excluded from prospective studies from which predictive models for recurrent VTE after completion of treatment for a first event were derived. 67 A meta-analysis of individuals with AT deficiency concluded the odds of recurrence were increased 2-4-fold with an absolute annual recurrence risk without long-term anticoagulant therapy of 8.8% (95% CI: 4.6-14.1) for AT-deficient and 4.3% (95% CI: 1.5-7.9) for non-AT-deficient VTE patients.…”

Section: General Guidelines On the Role Of Thrombophilia Testingmentioning

confidence: 99%

See 1 more Smart Citation

Thrombophilia testing: A British Society for Haematology guideline

et al. 2022

View full text Add to dashboard Cite

This guideline was compiled according to the BSH process at [https://b-s-h.org.uk/media/ 16732/ bsh-guida nce-devel opmen tproce ss-dec-5-18.pdf]. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) nomenclature was used to evaluate levels of evidence and to assess the strength of recommendations. The GRADE criteria can be found at http://www.grade worki nggro up.org. A literature search was carried out using the terms given in Appendix S1 until April 2021. Review of the manuscriptReview of the manuscript was performed by the BSH Haemostasis and Thrombosis Task Force, the BSH Guidelines Committee and the sounding board of BSH. It was also placed on the members section of the BSH website for comment. It has also been reviewed by Royal College of Obstetricians and Gynaecologists, Royal College of Paediatrics and Child Health, Royal College of Physicians and Thrombosis UK, a patient-centred charity dedicated to promoting awareness, research and care of thrombosis; these organisations do not necessarily approve or endorse the contents. I N TRODUC TIONThis guideline updates and widens the scope of the previous British Society for Haematology (BSH) Clinical guidelines for testing for heritable thrombophilia 1 to include both heritable and acquired thrombophilia.

show abstract

Section: Thrombophilia Traits: Clinical Significance and Measurement ...mentioning

confidence: 97%

Section: General Guidelines On the Role Of Thrombophilia Testingmentioning

confidence: 99%

Thrombophilia testing: A British Society for Haematology guideline

et al. 2022

View full text Add to dashboard Cite

show abstract

“…A single-point mutation in the prothrombin G20210A gene is linked to augmented prothrombin levels and increased risks of venous thrombosis. 19 …”

Section: Discussionmentioning

confidence: 99%

Prevalence of the prothrombin G20210A mutation among ischemic stroke patients

Ahmed

Hameed

Hussen

et al. 2020

J Cardiovasc Thorac Res

View full text Add to dashboard Cite

Introduction: Ischemic stroke is characterized as a sudden neurological deficit attributed to an acute focal injury of the central nervous system by a vascular cause. This study was performed to determine the frequency of G20210A mutation in the prothrombin gene and its effectiveness on the incidence of ischemic stroke in the Erbil city of Kurdistan region, Iraq. Methods: A total of 50 patients with ischemic stroke was analyzed for the detection of prothrombin gene mutation (G20210A), using polymerase chain reaction (PCR), Restriction fragment length polymorphism (RFLP) with Hind III restriction enzyme. Results: We observed no evidence of an association between ischemic stroke and G20210A mutation in the prothrombin gene in this region. Conclusion: Our finding demonstrates that prothrombotic gene variant seems not to be linked to the incidence of ischemic stroke in Erbil region.

show abstract

“…Deoxyribonucleic acid (DNA) was extracted from frozen ethylenediaminetetraacetic acid whole blood collected at the time of the index VTE and used for polymerase chain reaction assays of the factor V Leiden (QIAamp DNA Blood Mini QIAcube kit, Qiagen AG, Hombrechtikon, Switzerland) and prothrombin G20210A mutation (Roche Diagnostics AG, Rotkreuz, Switzerland) in a core laboratory. 33 In patients who were not under anticoagulation anymore at 12 months after the index VTE, we also measured antithrombin activity as heparin cofactor using Coamatic LR Antithrombin (Chromogenix, Instrumentation Laboratory, Bedford, United States) on a BCS-XP coagulometer, protein C anticoagulant activity using STA-Staclot protein C reagent (Stago, France) and a BCS-XP coagulometer, and free protein S antigen using Innovance Free PS Ag reagent on a CS5100 coagulometer (Siemens, Germany) in citrated platelet-poor plasma from a second blood sample. 34 Antithrombin, protein C, and free protein S were expressed as a percentage of international standard normal plasmas calibrated by the manufacturers.…”

Section: Methodsmentioning

confidence: 99%

Do Patients with a Family or Personal History of Venous Thromboembolism have an Increased Risk of Recurrence?

et al. 2021

View full text Add to dashboard Cite

Background A family (FH) and personal history (PH) of venous thromboembolism (VTE) are commonly evaluated risk factors for recurrence. We examined the association between FH/PH of VTE and the risk of recurrence and whether a stronger history status (i.e., both FH/PH vs. no FH/PH) carries an increased recurrence risk. Methods We prospectively followed 813 patients aged ≥ 65 years with acute VTE from 9 Swiss hospitals. We classified patients into four groups: no FH/PH, FH only, PH only, and both FH/PH. The primary outcome was recurrent VTE during the full observation period. We examined the association between FH/PH status and the time to VTE recurrence using competing risk regression, adjusting for confounders and periods of anticoagulation. Results Of 813 patients with VTE, 59% had no FH/PH, 11% a FH only, 24% a PH only, and 7% had both a FH and PH of VTE. Overall, 105 patients had recurrent VTE during the full observation period. After adjustment, patients with a FH only (subhazard ratio [SHR] 0.8, 95% confidence interval [CI] 0.4–1.7), PH only (SHR 1.5, 95% CI 0.9–2.5), and both FH/PH (SHR 1.4, 95% CI 0.6–3.1) did not have an increased risk of recurrent VTE compared with those without FH/PH. When we considered the period after the completion of initial anticoagulation only, the results were similar. Conclusion Our findings indicate that in patients with acute VTE, a FH and/or PH of VTE does not convey an increased risk of recurrent VTE. In particular, we did not find a “dose–effect” relationship between FH/PH status and VTE recurrence.

show abstract

Do Factor V Leiden and Prothrombin G20210A Mutations Predict Recurrent Venous Thromboembolism in Older Patients?

Cited by 5 publications

References 14 publications

Thrombophilia testing: A British Society for Haematology guideline

Thrombophilia testing: A British Society for Haematology guideline

Prevalence of the prothrombin G20210A mutation among ischemic stroke patients

Do Patients with a Family or Personal History of Venous Thromboembolism have an Increased Risk of Recurrence?

Contact Info

Product

Resources

About